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Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo- and
radiotherapy. Drug resistance can be induced by epigenetic changes such
as aberrant DNA methylation. To overcome drug resistance, we explored a
promising approach based on the use of 5-aza-20-deoxycytidine (AZA), a
demethylating agent, in combination with the mTOR inhibitor everolimus
in MTC cells (MZ-CRC-1 and TT). This combined treatment showed a
strong synergistic antiproliferative activity through the induction of apop-
tosis. The effect of everolimus and/or AZA on genome-wide expression
profiling was evaluated by Illumina BeadChip in MZ-CRC-1 cells. An
innovative bioinformatic pipeline identified four potential molecular path-
ways implicated in the synergy between AZA and everolimus: PI3K-Akt
signaling, the neurotrophin pathway, ECM/receptor interaction, and focal
adhesion. Among these, the neurotrophin signaling pathway was most
directly involved in apoptosis, through the overexpression of NGFR and
Bax genes. The increased expression of genes involved in the NGFR-
MAPK10-TP53-Bax/Bcl2 pathway during incubation with AZA plus evero-
limus was validated by western blotting in MZ-CRC-1 cells. Interestingly,
addition of a neutralizing anti-NGFR antibody inhibited the synergistic
cytotoxic activity between AZA and everolimus. These results open a new
therapeutic scenario for MTC and potentially other neuroendocrine
tumors, where therapy with mTOR inhibitors is currently approved.
1. Introduction
Medullary thyroid cancer (MTC) is a neuroendocrine
tumor originating from parafollicular C cells, and it is
highly resistant to chemo- and radiotherapy (Vitale
et al., 2001). The hyperactivation of the PI3K/Akt/
mTOR cascade has a relevant role in the pathogenesis
and progression of MTC. In fact, most of the
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pro-oncogenic effects of RET and RAS mutations are
modulated by the activation of PI3K/Akt/mTOR
pathway (Lyra et al., 2014; Manfredi et al., 2015).
Few preliminary studies showed promising antitumor
effects of mTOR inhibitors, such as everolimus, in
MTC (Druce et al., 2012; Faggiano et al., 2012;
Heilmann et al., 2016; Lim et al., 2013). A recent
phase II study, assessing efficacy and tolerability of
everolimus on tumor progression in patients with
advanced thyroid cancer, showed stable disease in five
(71%) of seven patients with MTC and a low toxicity
profile for everolimus (Schneider et al., 2015).
Although everolimus has been reported to inhibit
cell proliferation and angiogenesis in several human
tumors, long-term treatment with mTOR inhibitors
can be frustrated by the induction of resistance. More-
over, the anticancer effect of everolimus may be lim-
ited because of the intrinsic lack of inhibition on
mTORC2 and the activation of survival pathways in
cancer cells (Chan and Kulke, 2014). On this basis,
anticancer treatment with everolimus as monotherapy
may not be optimal, supporting the rationale for a
combined treatment approach with other targeted
agents.
Epigenetic alterations, including dysregulated pro-
tein acetylation and DNA methylation, affect gene
expression and contribute to tumorigenesis in several
tumors (Hervouet et al., 2013; Walenkamp et al.,
2014), including MTC (Vitale et al., 2016). PI3K/Akt/
mTOR pathway is frequently deregulated in several
malignancies through epigenetic alterations (Goel
et al., 2004). Epigenetic alterations appear to be also
implicated in the development of resistance to mTOR
inhibitors (Bihani et al., 2015; Juengel et al., 2012). In
fact, histone deacetylase inhibitors are able to resensi-
tize renal carcinoma cells to mTOR inhibitors (Bihani
et al., 2015; Juengel et al., 2012, 2014). However, most
of the epigenetic mechanisms of resistance to mTOR
inhibitors, particularly those concerning aberrant
DNA methylation, remain poorly defined.
In this article, we have explored a novel approach
to potentiate the antitumor activity of everolimus,
based on the use of 5-aza-20-deoxycytidine (AZA), a
well-established demethylating agent, in MTC.
2. Materials and methods
2.1. Cell lines and reagents
Everolimus and AZA were kindly supplied by Novar-
tis Pharma (Basel, Switzerland) and Sigma-Aldrich (St.
Louis, MO, USA), respectively. Both drugs were
dissolved in DMSO and stored at 20 °C. Human
MTC cell lines (MZ-CRC-1 and TT) were provided
from Prof. Lips (Utrecht, the Netherlands). Both cell
lines were cultured at 37 °C and 5% CO2 in F-12 with
Kaighn’s modification medium supplemented with
10% fetal bovine serum, 2 nM glutamine, and
105 UL1 penicillin/streptomycin. HEK-293 (ATCC)
human embryonic kidney cell line was cultured at
37 °C and 5% CO2 in DMEM high glucose medium,
without sodium pyruvate, supplemented with 10%
fetal bovine serum, 2 nM glutamine, and 105 UL1
penicillin/streptomycin.
2.2. Cell viability assessment
MTC cells were plated in 96-well plates (3 9 104 cells
per well) and treated with various concentrations of
compounds (range 101–102 nM for everolimus, 103–
105 nM for AZA). Cells growing in drug-free medium
and vehicle-treated were used as control. After 3 days,
medium and drugs were replaced. After 6 days, viabil-
ity of cells was measured by the MTT assay (3-(4,5-
dimethylthiazol-2-yl)-2.5-diphenyltetrazolium), as pre-
viously described (Vitale et al., 2012). Under the same
conditions, the in vitro toxicity of everolimus and
AZA at synergistic concentrations was examined
through MTT assay in HEK-293 cells.
2.3. Drug combination studies
MTC cells were seeded in 96-well plates with medium
without and with everolimus and/or AZA at different
concentrations. After 3 days, medium and compounds
were refreshed. Cell viability was evaluated after
6 days of treatment using MTT assay. Three combina-
tions were tested for each schedule: equiactive doses of
the two agents (IC50), higher relative doses of everoli-
mus (IC75 of everolimus/IC25 of AZA), and higher rel-
ative doses of AZA (IC25 of everolimus/IC75 of AZA).
Assessment of synergistic interaction between drugs
was made with CALCUSYN software (Biosoft, Ferguson,
MO, USA). Combination index (CI) values of < 1, 1,
and > 1 are suggestive of synergy, additivity, and
antagonism, respectively (Chou and Talalay, 1984;
Chou et al., 1994). We also evaluated the dose reduc-
tion index (DRI), providing the magnitude of how
much the dose of each drug in a synergistic combina-
tion may be reduced at a given effect level compared
with the doses of each drug alone; the potentiation
factor, defined as the ratio of the IC50 of either everoli-
mus or AZA alone to the IC50 of everolimus and AZA
in combination.
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2.4. Cell cycle analysis
Cells were plated in six-well plates (3 9 105 cells/well)
in duplicate with medium without (control group) and
with everolimus and/or AZA. After 3 days, medium
and drugs were refreshed. After 6 days, cells were col-
lected, stained with propidium iodide (PI) (Sigma-
Aldrich), and analyzed using a FACScalibur flow
cytometer (Becton Dickinson, Erembodegem, Belgium)
and CELLQUEST PRO Software, as previously described
(Vitale et al., 2007).
2.5. Flow cytometric analysis of apoptosis
Cells were plated in six-well plates and incubated with
everolimus and/or AZA, as reported in the section of
cell cycle analysis. After 6 days of treatment, cells were
collected and stained with Annexin V-FITC (BD
Pharmingen, San Diego, CA, USA) and PI, and all
samples were analyzed with FACScalibur, as previ-
ously reported (Vitale et al., 2006).
2.6. Western blot
MZ-CRC-1 cells were plated in six-well plates and
incubated with everolimus and/or AZA, as previously
reported. After 6 days of treatment, cells were scraped,
washed in PBS, and resuspended in RIPA lysis buffer.
Lysates were centrifuged, and protein analysis was
conducted on supernatant. Cell extracts (50 lg per
lane) were separated on NuPage 4–12% Bis/Tris Gels
and transferred with iBlot System (Life Technologies,
Carlsbad, CA, USA). Membranes were blocked with
5% milk TBS-T and incubated with specific antibodies
overnight at 4 °C: anticaspase-3 and poly(ADP-ribose)
polymerase (PARP), anticleaved caspase-3 and PARP,
anti-Bcl2, anti-Bax, anti-mTOR, anti-phospho-mTOR
(Ser2448), anti-4E-BP1, anti-phospho-4E-BP1 (Ser 65),
anti-MAPK10, anti-phospho-MAPK8/9/10 (Thr183/
Tyr185), anti-phospho-p53 (Ser15) (Cell Signaling
Technology, Beverly, MA, USA), and anti-NGFR
(Sigma-Aldrich). Blots were detected by the Luminata
Forte ECL Kit (Millipore, Darmstadt, Germany) after
incubation with HRP-conjugated mouse and rabbit
secondary antibodies (dilution 1 : 1000 for anti-
MAPK10, anti-phospho-MAPK8/9/10 and anti-phos-
pho-p53; 1 : 5000 for anticaspase-3; and 1 : 10 000
for other antibodies) and then exposed to X-ray
film. Bands of interest were quantified through IM-
AGEJ software version 1.47 (Wayne Rasband, NIH,
Bethesda, MA, USA). Results were normalized
against the level of actin expression in each sample,
and the intensities of the bands were expressed as
arbitrary units when compared to those of the
untreated cells.
2.7. Gene expression profiling
MZ-CRC-1 cells were seeded in six-well plates and
treated with everolimus and/or AZA, as previously
reported. After 6 days, total RNA was extracted using
Trizol Reagent (Life Technologies) and purified by
RNeasy Mini Kit (Qiagen, Hilden, Germany). Amplifi-
cation-grade DNase I (Life Technologies) was used to
eliminate residual genomic DNA from RNA samples.
Samples with an A260/A280 ratio falling in the range
1.8–2.1 were used for experiments.
The Illumina TotalPrep RNA Amplification Kit
(Ambion, Foster City, USA) was employed using
200 ng of total RNA as starting material. Labeled
cRNA (750 ng) was hybridized to human HT-12 v3
BeadChip arrays (Illumina, San Diego, CA, USA)
according to the manufacturer’s recommendation. Flu-
orescent images were obtained with a BeadArray
reader and processed with the BEADSCAN software (Illu-
mina, San Diego, CA, USA).
2.8. Microarray gene expression analysis
Significance analysis of microarray was employed to
identify differentially expressed genes (DEGs) by com-
paring the expression value of each gene between every
group of treatment vs the untreated control, as previ-
ously described (Tusher et al., 2001). All the delta val-
ues were selected in order to provide a false discovery
rate < 0.05. Once determined the DEGs, the next step
was to discover which biological pathways were associ-
ated with the list of DEGs through signaling pathway
impact analysis (SPIA) (Tarca et al., 2009), an algo-
rithm of third generation that takes in consideration
not only the identity of the genes but also the topology
of the pathway. These aspects were reported by the
probability values: pPERT (reflecting the amount of
perturbation measured in each pathway) and pNDE
(probability of obtaining a number of DEGs on the
given pathway at least as large as the observed one).
These two types of evidence, pPERT and pNDE, were
finally combined into one global probability value,
pGFdr, which was used to rank the pathways and to
test the research hypothesis that the pathway was sig-
nificantly involved in the condition under the study.
To refine the SPIA, a downstream analysis based on
the structural equation modeling (SEM) was per-
formed (Pepe and Do, 2015; Pepe and Grassi, 2014).
The method consists in the understanding how the
DEGs, source of perturbation, propagated the
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perturbation in the biological network composed by
the significant pathways. The module was obtained by
the detection and fusion in a unique model of all direc-
ted shortest paths that put in communication the
DEGs present in the significant pathways. This
allowed (a) to overcome the limits of the classical
pathway analysis that considers the pathways as sepa-
rate entities and (b) to detect the biological network
where the drug modules are searched.
2.9. DNA preparation and infinium methylation
450K array
MZ-CRC-1 cells were plated in six-well plates and
treated with everolimus and/or AZA, as previously
reported. After 6 days, total DNA was extracted using
the DNeasy Blood & Tissue Kit (Qiagen). Quality con-
trol and quantification of DNA were performed before
and after bisulfite conversion. DNA was quantified
with NanoDrop (NanoDrop Products Thermo Scien-
tific, Wilmington, DE, USA) and by fluorometric read-
ing (Quant-iTTM PicoGreen dsDNA Assay Kit);
quality was assessed by visualization of genomic DNA
on 1% agarose gel electrophoresis. Only nonfragmen-
ted DNA samples with a concentration higher than
50 nglL1 were subsequently processed. The genomic
DNA was treated with sodium bisulfite using the EZ
DNA Methylation KitTM (Zymo Research, Irvine, CA,
USA); the technique requires only 500 ng of input
DNA. Four microliters of bisulfite-converted DNA
were used for hybridization on Infinium
HumanMethylation 450K BeadChip, according to Illu-
mina’s standard protocol. Data were acquired through
Illumina HiScan SQ scanner. Image intensities were
extracted using GENOMESTUDIO software v2010.3 (Illu-
mina). The methylation score for each CpG site was
represented as b-values according to the fluorescent
intensity ratio between methylated and unmethylated
probes. b-Values may range between 0 (completely
unmethylated) and 1 (completely methylated). Illumina
Methylation 450K raw data were analyzed using the
RNBEADS analysis software package (Assenov et al.,
2014). Sites overlapping SNPs were firstly removed
from the analysis as well as probes on sex chromo-
somes. Probes and samples of highest impurity were
removed from the dataset using the Greedycut algo-
rithm. We have considered every b-value to be unreli-
able when its corresponding detection P-value was not
below the threshold (T = 0.05). The background was
subtracted using the methylumi package (method
‘noob’). The signal intensity values were normalized
using the SWAN normalization method, as imple-
mented in the minfi package (Aryee et al., 2014). The
‘Shapiro.test’ function provided in the R package
‘stats’ was applied to test normality among variables.
The ‘kruskal.test’ function provided in the R package
‘stats’ was used to test differences among treated and
untreated groups for all nonparametric data. DunnT-
est provided in the R package ‘dunn.test’ has been
applied as post hoc test.
2.10. Statistical analysis
All experiments were performed at least three times.
Statistical differences among groups were first evalu-
ated by the ANOVA test, followed by post hoc test
(Newman–Keuls). A P value < 0.05 was considered
significant. The values reported in the figures represent
the mean  standard error of the mean. For statistical
analysis, GRAPHPAD PRISM 5.0 was used (GraphPad
Software Inc., La Jolla, CA, USA).
3. Results
3.1. Pharmacological combination between
everolimus and AZA on cell proliferation
In MZ-CRC-1 cells, the combination of everolimus
and AZA was highly synergistic when either of the
two drugs was used with lower concentrations of ever-
olimus (IC25 everolimus:IC75 AZA) or with equitoxic
concentrations (IC50 everolimus:IC50 AZA) (Table 1,
Fig. 1). The DRI50 (DRI calculated for 50% cell sur-
vival) was 8.8 for everolimus and 101 for AZA (when
drugs were used at IC25 everolimus:IC75 AZA) and 4.3
for everolimus and 590 for AZA (at equitoxic concen-
trations) (Table 1).
In TT cells, a synergistic activity was similarly
detected when lower concentrations of everolimus were
adopted (IC25 everolimus:IC75 AZA), while antagonis-
tic effects were observed with relatively higher concen-
trations of everolimus (IC75 everolimus:IC25 AZA)
(Table 1, Fig. 1).
The optimal results (lowest CI values) were obtained
when the two drugs were used at lower doses of evero-
limus in MZ-CRC-1 cells. Therefore, we have per-
formed subsequent experiments using 2.1 nM (IC25) of
everolimus and/or 1.4 9 102 nM (IC75) of AZA in
MZ-CRC-1 cells.
3.2. In vitro toxicity assessment
The effect of drug combination on the cell viability of
HEK-293 cell line, derived from human embryonic
kidney cells, was evaluated through MTT assay to
roughly predict the toxicity profile of both everolimus
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and AZA in a noncancer cell model. Combined treat-
ment with everolimus and AZA, at concentrations
showing synergistic antiproliferative activity in MZ-
CRC-1 cells, inhibited viability of HEK-293 cells
(25%) to a lesser extent than that detected in MTC
cells (54%) (Fig. 2A). Moreover, we did not observe
any change in morphology of HEK-293 cells after
treatment with everolimus and AZA compared to
untreated control (Fig. 2B).
3.3. Effects of everolimus and AZA on cell cycle
AZA alone slightly, but significantly decreased cell
population in G0/G1 phase (6% vs untreated control,
P < 0.05) and increased cell number in G2/M phase
(+23% vs untreated control, P < 0.01), suggesting a
cell cycle arrest in G2/M phase (Fig. 3). Everolimus
alone significantly decreased cells percentage in both S
(24% vs untreated control, P < 0.05) and G2/M
Fig. 1. Evaluation of synergism between everolimus (EV) and 5-aza-20-deoxycytidine (AZA) in medullary thyroid cancer cells by isobologram
analysis. These experiments were performed with MTT assay. Combination index (CI)/fractional effect curves were elaborated with the
dedicated software CALCUSYN (developed by Chou and Talalay) as described in Materials and methods. Curves show the CI vs the fraction of
medullary thyroid carcinoma cells MZ-CRC-1 (A–C) and TT (D–F) affected by the EV/AZA combinations at 50 : 50 (A/D), 25 : 75 (B/E),
75 : 25 (C/F) cytotoxic ratios. CI represents the assessment of synergy induced by drug interaction. In detail, CI values of < 1, 1, and > 1
indicate synergy, additivity, and antagonism, respectively. Each point (represented in graph by x-mark) is the mean of at least four different
replicates. The statistical significance of each point was evaluated with ANOVA, and the derived P values were always less than 0.01.
Table 1. Combination index (CI), dose reduction index (DRI), and potentiation factor (PF), according to the different cytotoxic ratio of
everolimus (EV) and 5-aza-20-deoxycytidine (AZA) combination in MZ-CRC-1 and TT cell lines after 6 days of treatment.
Cell line Cytotoxic ratio
ED50 (nM)
CI50
a
DRI50
b PFc
InterpretationEV AZA EV AZA EV AZA
MZ-CRC-1 EV-AZA (50 : 50) 12.4 35.6 0.2 4.3 5.9 9 102 1.8 1.1 9 103 Strong synergism
EV-AZA (25–75) 2.1 1.4 9 102 0.1 8.8 1.0 9 102 10.4 2.8 9 102 Strong synergism
EV-AZA (75–25) 1.3 9 102 3.2 9 101 2.3     Antagonism
TT EV-AZA (50 : 50) 9.2 3.4 9 101 1.3     Antagonism
EV-AZA (25–75) 1.2 8.0 0.7 1.5 6.4 9 102 6.1 11 Synergism
EV-AZA (75–25) 91.1 1.2 9 103 17     Antagonism
aCI50 was calculated for 50% cell survival (ED50) by isobologram analyses performed with CALCUSYN software.
bDRI was calculated in case of synergism. It represents the order of magnitude (fold) of dose reduction obtained for ED50 effect in combina-
tion setting as compared to each drug alone.
cPF was calculated in case of synergism as the ratio between the IC50 of either everolimus or AZA alone and the IC50 of everolimus or AZA
in combination setting.
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phase (15% vs untreated control, P < 0.05). This
effect was comparable to that observed during the syn-
ergistic combination of everolimus plus AZA (S phase:
27% vs untreated control, G2/M phase: 14% vs
untreated control, both P < 0.05, Fig. 3).
3.4. Effects of everolimus and AZA on apoptosis
Everolimus did not change the percentages of early
apoptotic and late apoptotic/necrotic cells compared
with the untreated control. AZA induced a statistically
nonsignificant increase in the population of late apop-
totic/necrotic cells. Interestingly, the AZA/everolimus
combination significantly increased the percentage of
early apoptotic (+35% vs control, P < 0.05) and late
apoptotic/necrotic (+90% vs control, P < 0.001) cells
(Fig. 4A).
Western blot analysis of key executioners of apopto-
sis, such as caspase-3 and PARP, further confirmed
these data (Fig. 4B,C). After 6 days of treatment, the
Fig. 2. In vitro toxicity profile of everolimus (EV) and 5-aza-20-deoxycytidine (AZA). Cells were treated for 6 days with EV (2.1 nM) and/or
AZA (1.4 9 102 nM). (A) The cytotoxicity was measured by MTT cell viability assay in HEK-293 and MZ-CRC-1 cell lines. (B) The morphology
of HEK-293 cells was determined after 6 days of exposure to drug-free medium (CTR) and EV plus AZA. Images were captured using a
phase-contrast microscopy at 9 20 magnification. ***P < 0.001.
Fig. 3. Cell cycle distribution, detected by FACS analysis, in propidium iodide-stained MZ-CRC-1 cells after 6 days of treatment with 2.1 nM
everolimus (EV) and/or 1.4 9 102 nM 5-aza-20-deoxycytidine (AZA). Control values have been set to 100%. *P < 0.05 **P < 0.01.
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AZA/everolimus combination significantly increased
caspase-3 degradation, resulting in increased expres-
sion of cleaved caspase-3 and decreased expression of
full caspase-3. A moderate increase in cleaved caspase-
3 has been detected after AZA alone. Similarly, the
activity of PARP was moderately stimulated after
6 days of treatment with AZA, and its combination
with everolimus enhanced again this effect. No signifi-
cant changes in caspase-3 activity and PARP cleavage
were detected after the incubation of MZ-CRC-1 cells
with everolimus alone.
3.5. Effects of everolimus and AZA on mTOR
activation
No detectable impact on total mTOR and 4E-BP1
protein levels has been observed during incubation
with everolimus and/or AZA in MZ-CRC-1 cells
(Fig. 5). Everolimus alone significantly reduced both
mTOR and 4E-BP1 phosphorylation. A similar effect
has been observed after everolimus in combination
with AZA, while AZA alone did not significantly
affect this process (Fig. 5).
3.6. Gene expression analysis
To clarify the molecular bases for synergy between
these two compounds, gene expression profiles with or
without everolimus and/or AZA treatment were evalu-
ated in MZ-CRC-1 cells. Following treatment with
everolimus or AZA alone, 72 DEGs (Table S1) and 16
DEGS (Table S2) were identified, respectively. On the
other hand, 74 DEGs were identified following incuba-
tion with everolimus and AZA (Table S3).
On each list of DEGs, a pathway analysis was per-
formed with SPIA, which calculated the statistical
Fig. 4. Effects of 2.1 nM everolimus (EV) and/or 1.4 9 102 nM 5-aza-20-deoxycytidine (AZA) on apoptosis in MZ-CRC-1 cells after 6 days of
incubation. (A) Flow cytometry with Annexin V and propidium iodide. Values of early apoptotic cells and late apoptotic/necrotic cells were
expressed as percentage compared with the untreated control. (B) Representative western blot analysis of apoptotic markers (full and
cleaved forms of caspase 3 and PARP). Actin was used as a loading control. (C) Quantification of western blot analysis from at least three
independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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significance of pathways by considering their topology
and the expression levels of their genes. Only for the
comparisons between everolimus vs control and AZA/
everolimus combination vs control, significant path-
ways were detected (Tables 2 and 3). The significant
pathways modulated after everolimus treatment
(Table 2) were PI3K-Akt signaling pathway and com-
plement and coagulation cascades. SPIA revealed four
significant pathways in the group treated with the syn-
ergistic AZA/everolimus combination (Table 3): PI3K-
Akt signaling, neurotrophin signaling pathway, ECM/
receptor interaction, and focal adhesion.
The module network obtained by the fusion of the
four significant pathways in the group treated with the
AZA/everolimus combination is described in Fig. 6.
Edges represent interactions between two genes. The
list of genes in the module is reported in Table S4. All
the DEGs reported in Fig. 6 were overexpressed com-
pared to the untreated control. The SEM multigroup
analysis was performed comparing the covariance
matrices implied by the model for the treatment data
against the control data. The likelihood ratio test had
a P-value of 0.002, confirming that the module was
differentially regulated between the groups. The per-
turbed connections identified in this module are
reported in Table 4.
Considering the perturbed edges (Table 4), the links
between the NGFR and BAX are found to be signifi-
cant and intriguing because they are involved in the
process of apoptosis (Fig. 6). NGFR was overex-
pressed during exposure to the AZA/everolimus com-
bination compared to untreated control. In the same
condition, the activation of RAC1 (mediated by
NGFR) and the indirect interaction RAC1/MAPK10
were found to be stimulated (Table 4). It has been pre-
viously reported that the activation of MAPK10
(JNK3), mediated by NGFR/RAC1, can induce apop-
tosis through the increased expression of TP53 and
Table 2. Significant pathways associated with treatment with
everolimus by SPIA in MZ-CRC-1 cells.
Pathway name pPERT pNDE pGFdr
PI3K-Akt signaling pathway 0.066 0.0013 0.036
Complement and coagulation
cascades
0.493 0.0005 0.048
pPERT, probability of observing a total accumulated perturbation of
the pathway more extreme than expected by chance; pNDE, prob-
ability of obtaining a number of DEGs in the given pathway at least
as large as the observed one; pGFdr, false discovery rate for the
global P-value from the combination of pPERT and pNDE.
Table 3. Significant pathways associated with treatment with
everolimus plus AZA by SPIA in MZ-CRC-1 cells.
Pathway name pPERT pNDE pGFdr
PI3K-Akt signaling pathway 0.102 0.0002 0.0178
Neurotrophin signaling pathway 0.689 0.0002 0.0308
ECM/receptor interaction 0.115 0.0013 0.0308
Focal adhesion 0.199 0.0018 0.0415
pPERT, probability of observing a total accumulated perturbation of
the pathway more extreme than expected by chance; pNDE, prob-
ability of obtaining a number of DEGs in the given pathway at least
as large as the observed one; pGFdr, false discovery rate for the
global P-value from the combination of pPERT and pNDE.
Fig. 5. Effects of 2.1 nM everolimus (EV) and/or 1.4 9 102 nM 5-aza-20-deoxycytidine (AZA) on protein expression of total and
phosphorylated mTOR and 4E-BP1 in MZ-CRC-1 cells after 6 days of incubation. (A) Representative western blot analysis. Actin was used
as a loading control. (B) Quantification of western blot analysis from at least three independent experiments. *P < 0.05; **P < 0.01.
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BAX (Aloyz et al., 1998; Kenchappa et al., 2010).
Although in our model the path TP53?BAX was not
significantly perturbed during incubation with the
AZA/everolimus combination, an increase in BAX
expression was detected during synergistic treatment.
The same procedure was applied for the two path-
ways (Table 2) previously identified during everolimus
treatment. The directed shortest paths between the
DEGs in the significant KEGG pathways generated
the module reported in Fig. S1. The list of genes in the
module is described in Table S5. SEM was used to
verify whether globally the strength of connections
was statistically different between control and everoli-
mus in the assessed modules, but significant differences
Fig. 6. Perturbed pathway module in the group treated with everolimus and 5-aza-20-deoxycytidine. The green nodes are the DEGs, and the
yellow nodes represent the non-DEGs microarray genes that connect the DEGs. Edges represent interactions between two genes.
Table 4. Perturbed connections in the everolimus plus AZA module compared to the untreated control. The estimation of the strength
connection and P-value for ‘control’, ‘everolimus plus AZA’, and the ‘difference between everolimus plus AZA vs control’ are reported. We
have only included the connections where a statistically significant P value has been observed for the ‘difference between everolimus plus
AZA vs control’.
Path Type of process
Control Everolimus + AZA Difference
Estimate P value Estimate P value Estimate P value
MDM2?TP53 Inhibition 0.8271 0.0001 0.9864 0.0022 1.8135 0.0000
NGFR?ARHGDIB Binding/association 0.8935 0.0001 2.7208 0.0001 1.8273 0.0125
EPHA2?IRS1 Activation 0.5077 0.0079 0.3521 0.2699 0.8598 0.0208
PIP5K1C?VCL Indirect 0.6464 0.0237 0.3072 0.0001 0.9536 0.0013
VCL?ACTN1 Binding/association 0.0985 0.8827 2.4853 0.0002 2.5839 0.0062
ITGA1?PTK2 Binding 0.3282 0.0206 0.1908 0.2790 0.5190 0.0218
NGFR?RAC1 Activation 0.9042 0.0180 0.5223 0.0155 1.4265 0.0012
RAC1?MAPK10 Indirect 0.0499 0.6359 0.5799 0.0001 0.5300 0.0033
NGFR?CDC42 Activation 0.2736 0.3068 1.0567 0.0001 1.3303 0.0004
PAK1?MAP2K1 Phosphorylation 0.4008 0.0018 0.0669 0.0998 0.4678 0.0005
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were not detected (P-value: 0.1144). Therefore, addi-
tional analyses were not performed.
An enrichment analysis based on Disease Ontology
terms was performed on the genes selected in the mod-
ule related to the treatment with ‘everolimus plus
AZA’ (Fig. 7). Twenty-four of 25 identified terms were
tumors.
3.7. Validation of gene expression data
From the final model of perturbed biological pathways
during concomitant incubation with AZA/everolimus
combination (Fig. 6), NGFR-MAPK10-TP53-Bax/Bcl-
2 pathway was selected for further analysis on the
basis of its strict interaction and modulation of apop-
tosis, and assessed by western blot (Fig. 8). Indeed, in
our system, apoptosis was the cell death mechanism
responsible for the synergistic cytotoxic activity of
everolimus plus AZA.
A significant increase in NGFR expression has been
observed exclusively after 6 days of treatment with the
synergistic combination of everolimus plus AZA in
MZ-CRC-1 cells compared to untreated cells (Fig. 8).
Everolimus and AZA alone and in combination
increased the protein expression of MAPK10 and
phosphorylated MAPK8/9/10; these effects were more
pronounced with the combined treatment. In addition,
a significant increase in phosphorylated p53 was
observed only after incubation with everolimus and
AZA combination (Fig. 8). The proapoptotic and anti-
apoptotic Bax and Bcl-2, respectively, represent the
key proteins involved in mitochondrial pathway of
apoptosis. Western blot analysis showed that only the
synergistic combination of everolimus plus AZA signif-
icantly increased Bax with a concomitant decrease in
Bcl2 expression, while there was no significant change
in the expression of these proteins after the exposure
of MZ-CRC-1 cells to everolimus or AZA alone
(Fig. 8).
To verify that the synergistic antitumor activity
observed during AZA/everolimus coincubation was
indeed due to the increased expression in NGFR, we
assessed the effects of both drugs alone or in combina-
tion on MZ-CRC-1 cell proliferation and protein
expression of Bax and Bcl-2 after 6 days of treatment,
in the presence or absence of a neutralizing antibody
raised against NGFR (Fig. 9). The concomitant incu-
bation with blocking NGFR antibody counteracted
Fig. 7. Disease Ontology enrichment analysis for the genes selected in the significant perturbed module, in the group treated with
everolimus and 5-aza-20-deoxycytidine.
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the cytotoxic activity of everolimus and AZA alone,
and induced a moderate stimulation in cell prolifera-
tion after treatment with AZA/everolimus combination
(+20% vs control, P < 0.01, Fig. 9A). In a parallel set
of experiments performed without the incubation with
neutralizing antibody against NGFR, the more potent
antiproliferative activity after incubation with everoli-
mus plus AZA has been confirmed compared to single
drugs (Fig. 9B). During concomitant incubation with
neutralizing antibody against NGFR, everolimus plus
AZA induced a significant decrease in Bax and
increase in Bcl-2 expression, while these effects were
mild with each drug alone (Fig. 9C,D).
3.8. Effects of everolimus and AZA on DNA
methylation profile
Methylation levels of genes identified in the perturbed
everolimus plus AZA module (Fig. 6 and Table S4)
were extrapolated from genome-wide methylation anal-
ysis using the Infinium HumanMethylation 450K
BeadChip array performed in MZ-CRC-1 with or with-
out treatment with everolimus and/or AZA. The array
covers 769 probes for these selected 31 genes. Methyla-
tion levels for these genes were found to be significantly
different among groups (P = 3.6 9 105) (Fig. S2A). A
significant reduction in DNA methylation levels has
been observed after incubation with AZA alone, simi-
lar to that observed after AZA plus everolimus com-
pared to untreated control. The incubation with
everolimus alone did not significantly modify DNA
methylation levels. These data were confirmed through
the density plot showing methylation-level distributions
of untreated and treated samples (Fig. S2B). A similar
trend has been observed for NGFR and MAPK10,
both methylated genes involved in the NGFR-
MAPK10-TP53-Bax/Bcl-2 pathway (Fig. S2C).
4. Discussion
Aberrant promoter methylation of tumor suppressor
genes plays a relevant role in the initiation and
Fig. 8. (A) Representative western blot analysis of NGFR, MAPK10, phosphorylated MAPK8/9/10, phosphorylated p53, Bax, and Bcl-2
performed in MZ-CRC-1 cells without (CTR) or after incubation with 2.1 nM everolimus (EV) and/or 1.4 9 102 nM 5-aza-20-deoxycytidine
(AZA). Actin was used as a loading control. (B) Quantification of western blot analysis from at least three independent experiments.
*P < 0.05; **P < 0.01; ***P < 0.001.
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progression of cancer. In addition, it is being increas-
ingly recognized that aberrant DNA methylation
seems to be involved in the development of drug resis-
tance through transcriptional suppression of genes
implicated in drug metabolism, apoptosis, cell cycle
control, and other biological processes (Hervouet
et al., 2013). Taking into consideration that DNA
methylation is a reversible event unlike genetic muta-
tions, the use of demethylating agents has been
recently proposed as a new therapeutic strategy in can-
cer. Several reports demonstrated the capability of
AZA to overcome resistance to chemotherapeutic and
biological agents in tumors (Oronsky et al., 2014;
Vijayaraghavalu et al., 2013; Zhang et al., 2009). This
was encouraging, given that AZA is clinically used for
patients with acute myeloid leukemia and myelodys-
plastic syndromes.
In the current study, combination analysis, based on
the Chou–Talalay’s method, definitely demonstrated
that AZA combined with everolimus was more effec-
tive in inhibiting cell proliferation than each agent
alone in MTC cells. This cytotoxic activity was highly
synergistic through a potent induction of apoptosis in
MZ-CRC-1 cells, which was the cell line most resistant
to everolimus alone. However, in TT cells, combined
treatment exhibited both synergistic and antagonistic
effects on cell proliferation inhibition, depending on
the concentration of the drugs. In MZ-CRC-1 cells,
while everolimus or AZA alone was barely effective in
apoptosis induction, the AZA/everolimus combination
doubled the fraction of MTC apoptotic cells compared
to untreated controls. Cell cycle analysis showed that
everolimus decreased the percentages of MZ-CRC-1
cells in G2/M and S phases, but the combination with
AZA did not potentiate this effect. Interestingly, the
concentrations of AZA and everolimus adopted
in vitro for the synergistic antiproliferative activity can
be readily achieved in vivo with acceptable risk benefit
(van Groeningen et al., 1986; O’Donnell et al., 2008).
In addition, the in vitro toxicity of this combination
appeared to be moderate. The cytotoxic activity of
everolimus and AZA was lower in HEK-293 cells, a
human embryonic kidney normal cell line, compared
to that observed in MZ-CRC-1 cells. This is very
promising in terms of safety and tolerability for future
clinical trials.
Synergistic antiproliferative activity between AZA
and everolimus was not related to a direct effect on
Fig. 9. Effect of 2.1 nM everolimus (EV) and/or 1.4 9 102 nM 5-aza-20-deoxycytidine (AZA) on cell proliferation in MZ-CRC-1 cells (A, B) and
protein expression of Bax and Bcl-2 (C, D) after 6 days of treatment, in the presence (A, C, D) or absence (B) of neutralizing antibody
against NGFR (1 : 250). (C) Representative western blot analysis. Actin was used as a loading control. (D) Quantification of western blot
analysis from at least three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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mTOR activation. In fact, AZA was unable to potenti-
ate the inhibitory activity of everolimus on both mTOR
and 4E-BP1 phosphorylation in MZ-CRC-1 cells.
Gene expression analysis revealed potential molecu-
lar mechanisms implicated in the synergy of AZA and
everolimus in MZ-CRC-1 cells. We adopted an inno-
vative bioinformatic pipeline based on SPIA and
SEM, recently validated by one of us (Pepe and
Grassi, 2014), that allowed us to investigate pathway
modules, considering not only deregulated genes but
also the connections between the perturbed ones. Sev-
eral key regulatory genes modulated by the combined
treatment of AZA plus everolimus were identified by
this approach: PI3K-Akt signaling, neurotrophin sig-
naling pathway, ECM/receptor interaction, and focal
adhesion. Interestingly, all these pathways have a criti-
cal role in the regulation of both proliferation and
migration/invasion of tumor cells. In addition, a Dis-
ease Ontology enrichment analysis, performed on these
selected genes, identified 25 biological terms. Twenty-
four of 25 identified terms were tumors, including
endocrine gland cancer. The only noncancer item was
‘autosomal dominant disease’. These data further sup-
port the pivotal roles of these pathways in the develop-
ment and progression of MTC. Indeed, MTC is a
neuroendocrine tumor and MZ-CRC-1 cells harbor
the multiple endocrine neoplasia type 2B RET-M918T
mutation, transmitted in this disease as an autosomal
dominant trait (Santoro et al., 1995).
A perturbed pathway module, associated with the
combined treatment of everolimus plus AZA, was gen-
erated by the detection and fusion of all shortest paths
that put in communication the DEGs (Fig. 6). In this
network, the ‘neurotrophin signaling pathway’
appeared to exert a direct influence on the apoptotic
machinery through the overexpression of NGFR and
the activation of MAPK10-TP53-Bax pathway. Neu-
rotrophins are a family of proteins involved in differ-
entiation, plasticity, and survival of neurons and
modulate several functions of the neuroendocrine/im-
mune system (Fiore et al., 2009). This family includes
nerve growth factor (NGF), brain-derived neu-
rotrophic factor (BDNF), neurotrophins-3 (NT-3),
neurotrophins-4/5 (NT-4/5), and neurotrophins-6 (NT-
6). Biological activity of these factors is mediated
through the activation of Trk tyrosine kinase receptors
(TrkA, TrkB, and TrkC) and NGFR (also known as
p75 neurotrophin receptor, p75NTR) (Skaper, 2012).
In our study, gene expression analysis confirmed the
induction of apoptosis through the upregulation of
Bax. Bax is a proapoptotic protein antagonized by the
antiapoptotic Bcl-2. The ratio of Bax to Bcl-2 expres-
sion represents a cell death switch, which determines
the susceptibility of cells to an apoptotic stimulus.
Indeed, a selective decrease in Bax/Bcl-2 expression
represents a common mechanism of drug resistance in
tumor cells (Indran et al., 2011). We have found a
selective increase in the expression of Bax/Bcl-2 ratio,
validated through WB analysis, exclusively after treat-
ment with AZA and everolimus. This effect seems to
be associated with the upregulation of NGFR, which
has been described to be a tumor suppressor gene in
several tumors (Dimaras and Gallie, 2008; Jin et al.,
2007; Khwaja et al., 2004, 2006; Kuchler et al., 2011;
Kuner and Hertel, 1998; Wang et al., 2014; Yang
et al., 2015; Yuanlong et al., 2008), and consecutive
activation of MAPK10 and p53.
Although the specific role of NGFR in the tumori-
genesis and progression of MTC is unknown, neu-
rotrophin signaling pathway appears to be involved in
both preneoplastic thyroid C cell hyperplasia and
MTC progression through Trk receptors (McGregor
et al., 1999). In fact, a cross-talk between the signal
pathways mediated by the Ret proto-oncogene and
Trk receptors has been described (Esposito et al.,
2008; Peterson and Bogenmann, 2004).
The concomitant incubation with blocking NGFR
antibody counteracted the cytotoxic activity of everoli-
mus and AZA alone, and induced a moderate stimula-
tion in cell proliferation and a decrease in Bax/Bcl-2
ratio expression after treatment with AZA plus everoli-
mus compared to control. This effect could be
explained by the block of the proapoptotic pathway
mediated by NGFR, while the survival pathways
remained activated. These data confirmed that the
NGFR overexpression plays a main role in the syner-
gistic cytotoxic activity of these two compounds.
Although the mechanism by which the expression of
NGFR significantly increased during incubation with
everolimus and AZA remains unclear, in colorectal
cancer it has been recently reported that NGFR
expression was silenced by promoter methylation and
that the overexpression of this gene significantly inhib-
ited cell proliferation, invasion and stimulated cell
apoptosis (Yang et al., 2015). In our model, the over-
expression of NGFR appears not to be related to a
direct epigenetic effect on NGFR gene. In fact, during
incubation of MZ-CRC-1 cells with AZA, we found a
significant decrease in DNA methylation levels of
NGFR, comparable to that observed after everolimus
plus AZA, while NGFR expression increased exclu-
sively after combined treatment.
Intriguingly, the synergistic cytotoxic activity of
everolimus/AZA combination was more relevant in
MZ-CRC-1 (harboring RET-M918T mutation) than in
TT (harboring RET-C634W mutation) cells (Table 1).
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We cannot exclude that the type of RET genetic alter-
ation may have a role in the different antitumor activ-
ity observed in both cell lines. In fact, Gild et al.
(2013) demonstrated that oncogenic RET regulates
mTOR activity in MZ-CRC-1 and TT cell lines. Com-
bined incubation with RET and mTOR inhibitors
(AST487 and INK128, respectively) at low concentra-
tions cooperated to inhibit mTOR signaling and cell
growth, through the induction of apoptosis, in both
MTC cell lines. In addition, a recent study found that
methylation profiles relate closely to RET mutational
status in MTC, and the most distinctive methylome
was observed for RET-M918T-positive tumors
(Mancikova et al., 2017).
In conclusion, we described for the first time a syn-
ergistic cytotoxic activity combining AZA with everoli-
mus in MTC. This effect occurred through the
overactivation of NGFR-MAPK10-TP53-Bax/Bcl-2
pathway and the induction of apoptosis. These data
provide a new therapeutic scenario in MTC and prob-
ably in other neuroendocrine tumors, where therapy
with everolimus is currently approved.
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Fig. S1. Perturbed pathway module in the group trea-
ted with everolimus.
Fig. S2. (A) Box-and-whisker-plots showing global
methylation levels measured in 769 probes within 31
genes, selected from the perturbed module reported in
Figure 6, in MZ-CRC-1 cells without (CTR) or with
everolimus (EV) and/or 5-aza-20deoxycytidine (AZA).
(B) Density plot showing methylation level distribu-
tions of treated and untreated samples. (C) Box-and-
whisker-plots showing global methylation levels of
NGFR, MAPK10, TP53, BAX and BCL2 genes in
treated and untreated samples.
Table S1. Differentially expressed genes (DEGs) fol-
lowing incubation with everolimus vs untreated control
identified by Significance Analysis of Microarray
(SAM), using a delta value of 0.46. Fold change (FC).
Table S2. Differentially expressed genes (DEGs) fol-
lowing incubation with AZA vs untreated control iden-
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